Avro­bio takes a sec­ond stab at a good first im­pres­sion — but dura­bil­i­ty ques­tions still dog gene ther­a­py

Four months ago, Avro­bio’s shares $AVRO were sub­ject­ed to a rit­u­al slaugh­ter on Wall Street af­ter in­vestors were spooked by their lead gene ther­a­py …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.